Evidence map›Paper›PMID 27496363›Full record

ReviewExperimental hematology2016

Precision in donor selection: Identifying ideal stem-cell donors through their T cells.

Adam Widman, Ran Reshef

Open access · greenAbstract readReview
In one paragraph

Review in Experimental hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. A donor PD-1Signal transduction and targeted therapy · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Adam WidmanDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Ran ReshefBlood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY, USA. Electronic address: ran.reshef@columbia.edu.
Columbia University Irving Medical Center · US

Funding

A Mediterranean Diet in for Colon Cancer PreventionR01CA120381 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DJURIC, ZORA · 2007 to 2011
$1.8M
Lymphocyte trafficking blockade in allogeneic stem-cell transplantationK23CA178202 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RESHEF, RAN · 2013 to 2015
$520k
NCI NIH HHS K23 CA178202NCI NIH HHS R01 CA120381
6 · The paper itself

Abstract

HLA-identical siblings have always been considered ideal donors for allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in the treatment of hematologic cancers. Recent data suggest that we should rethink this paradigm. In "High Graft CD8+ Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning," we identified a group of stem-cell donors whose grafts contain an optimal composition of T-cells, leading to a dramatic decrease in disease relapse risk and an improvement in overall survival following allo-HSCT. To demonstrate this, we analyzed the outcomes of 200 patients with hematologic malignancies who underwent allo-HSCT after reduced-intensity conditioning (RIC). The analysis focused on T-cell content of peripheral blood stem-cell grafts. We found that higher graft CD8+ T-cell dose (CD8hi), a trait found only in grafts collected from young donors, was associated with improved survival due to a reduction in the risk for cancer relapse without a significant increase in graft-versus-host disease (GVHD). Though not all young donors mobilized CD8hi grafts, we found that a low CD4:CD8 ratio in the peripheral blood could identify these ideal donors prior to transplant. The likelihood of finding CD8hi donors correlated inversely with age, and elderly RIC transplant recipients had a low chance of receiving an ideal graft from their similarly aged siblings. Here, we examine these findings and their implications on choosing donors according to age and relatedness. We also explore biological mechanisms that determine the CD4:CD8 ratio in healthy donors.

Indexed as

Donor SelectionHematopoietic Stem CellsHematopoietic Stem Cell TransplantationPrecision MedicineT-LymphocytesAge FactorsAnimalsCD4-CD8 RatioGraft vs Host DiseaseHumansTransplantation, HomologousTransplantation ImmunologyTreatment Outcome

Identifiers

PMID27496363
PMCPMC5083192
OpenAlexW2477932914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.